Scholar Rock Holding Corp
apitegromab
spinal muscular atrophy (SMA)
Resolved
7days ago
Phase 3 readout · Jun 30, 2026
What's at stake
Phase 3 trial results for apitegromab in spinal muscular atrophy (SMA) are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“European launch expected in H2 2026, starting with Germany”